Literature DB >> 17987261

A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.

Yoshikazu Ogawa1, Teiji Tominaga.   

Abstract

OBJECTIVE AND IMPORTANCE: Thyrotroph cell adenoma accounts for only 1% of all pituitary adenomas. This tumor is tough and firm because of significant interstitial fibrosis, and is difficult to remove. Atypical adenoma has an aggressive biological character, invades the surrounding structures, and grows rapidly. Atypical thyrotroph cell adenoma is extremely rare. CLINICAL
PRESENTATION: A 32-year-old man presented with hyperthyroidism and bitemporal hemianopsia. Head magnetic resonance imaging revealed a large sellar tumor compressing the optic chiasma and invading the left cavernous sinus. INTERVENTION: Transsphenoidal surgery was performed and subtotal removal was achieved. Histological examination showed atypical thyrotroph cell adenoma. Gamma knife surgery was planned, but the tumor re-grew within 3 months, and reattached to the optic chiasma. Second transcranial surgery failed to remove residual tumor behind the pituitary stalk. Conventional irradiation followed by octreotide administration resulted in decreased tumor size and stable euthyroidism. The tumor has been controlled for 22 months since first surgery and diagnosis.
CONCLUSION: Atypical thyrotroph cell adenoma has an aggressive biological character and grows rapidly. Multimodal treatment including medication and radiotherapy is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17987261     DOI: 10.1007/s11060-007-9492-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

1.  Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma.

Authors:  N Sanno; A Teramoto; R Y Osamura
Journal:  J Neurosurg       Date:  2000-08       Impact factor: 5.115

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 3.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

4.  Ultrastructural characteristics of TSH-producing adenomas with special reference to its close similarity to BFA-treated pituitary adenoma cells.

Authors:  H Ikeda; Y Ogawa; T Yoshimoto
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 5.  Classification and pathology of pituitary tumors.

Authors:  George Kontogeorgos
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 6.  Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment.

Authors:  N Sanno; A Teramoto; R Y Osamura
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

7.  Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health.

Authors:  F Brucker-Davis; E H Oldfield; M C Skarulis; J L Doppman; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

Review 8.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

9.  Thyrotropin-secreting pituitary carcinoma.

Authors:  A J Mixson; T C Friedman; D A Katz; I M Feuerstein; J K Taubenberger; J M Colandrea; J L Doppman; E H Oldfield; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

10.  Hyperthyroidism secondary to a pituitary adenoma secreting TSH, FSH, alpha-subunit and GH.

Authors:  A W Patrick; S L Atkin; J MacKenzie; P M Foy; M C White; I A MacFarlane
Journal:  Clin Endocrinol (Oxf)       Date:  1994-02       Impact factor: 3.478

View more
  7 in total

1.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

2.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%.

Authors:  Y Ogawa; H Ikeda; T Tominaga
Journal:  J Endocrinol Invest       Date:  2009-05-21       Impact factor: 4.256

4.  Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.

Authors:  Marialaura Del Basso De Caro; Domenico Solari; Francesca Pagliuca; Alessandro Villa; Elia Guadagno; Luigi Maria Cavallo; Annamaria Colao; Guido Pettinato; Paolo Cappabianca
Journal:  Neurosurg Rev       Date:  2016-05-23       Impact factor: 3.042

5.  Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report.

Authors:  Nobuhiko Arai; Makoto Inaba; Takamasa Ichijyo; Hiroshi Kagami; Yutaka Mine
Journal:  J Med Case Rep       Date:  2017-01-06

6.  Thyroid-stimulating hormone-secreting pituitary adenoma presenting with recurrent hyperthyroidism in post-treated Graves' disease: a case report.

Authors:  Yoshikazu Ogawa; Teiji Tominaga
Journal:  J Med Case Rep       Date:  2013-01-21

7.  Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves' disease.

Authors:  Jiaqi Li; Huiwen Tan; Juan Huang; Dan Luo; Ying Tang; Ruichao Yu; Hui Huang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.